BACCHIARRI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 311
EU - Europa 133
AS - Asia 83
SA - Sud America 10
AF - Africa 3
OC - Oceania 1
Totale 541
Nazione #
US - Stati Uniti d'America 310
RU - Federazione Russa 55
IT - Italia 30
SG - Singapore 26
CN - Cina 17
HK - Hong Kong 17
IE - Irlanda 14
SE - Svezia 13
BR - Brasile 10
VN - Vietnam 9
KR - Corea 6
CH - Svizzera 4
DE - Germania 4
FI - Finlandia 4
GB - Regno Unito 3
IN - India 3
ES - Italia 2
FR - Francia 2
IQ - Iraq 2
AU - Australia 1
EG - Egitto 1
IR - Iran 1
KZ - Kazakistan 1
MX - Messico 1
NL - Olanda 1
NP - Nepal 1
TN - Tunisia 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 541
Città #
Santa Clara 53
Ashburn 44
Fairfield 35
Singapore 21
Seattle 18
Houston 16
Cambridge 15
Chandler 15
Dublin 14
Wilmington 14
Woodbridge 14
Hong Kong 13
San Jose 7
Milan 6
Seoul 6
Altamura 5
Florence 5
New York 5
Princeton 5
Ann Arbor 4
Beijing 4
Bern 4
Lawrence 4
Boardman 3
Boston 3
Kent 3
Los Angeles 3
Brooklyn 2
Chennai 2
Clifton 2
Hanoi 2
Ho Chi Minh City 2
Lauterbourg 2
Rome 2
San Diego 2
São Paulo 2
Turku 2
Almirante Tamandaré 1
Amsterdam 1
Araguaína 1
Baghdad 1
Baqubah 1
Barretos 1
Bismarck 1
Bologna 1
Brasília 1
Buffalo 1
Cagliari 1
Can Tho 1
Capurso 1
Chongqing 1
Cruz das Almas 1
Dallas 1
Duque de Caxias 1
Frankfurt am Main 1
Guadalajara 1
Haiphong 1
Jiaxing 1
Johannesburg 1
Kathmandu 1
Lagoa Nova 1
London 1
Manchester 1
Melbourne 1
Miano 1
Moscow 1
Mumbai 1
Munich 1
Naples 1
Pavlodar 1
Perugia 1
Phoenix 1
Poggibonsi 1
Redmond 1
Redwood City 1
Reston 1
Riverside 1
Salerno 1
Sant'Antimo 1
Sari 1
Shanghai 1
Stockholm 1
São José do Egito 1
Tanta 1
The Dalles 1
Tunis 1
Vyselki 1
Zibo 1
Totale 410
Nome #
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide 195
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 188
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 157
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. 8
Totale 548
Categoria #
all - tutte 1.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.659


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 2 2 0 1 0 3 1 0 1 6
2022/202374 6 12 5 9 5 10 9 7 7 0 0 4
2023/202415 0 3 3 0 0 2 1 3 0 0 3 0
2024/2025147 5 12 6 28 44 18 0 12 11 5 6 0
2025/2026153 18 15 5 8 24 10 14 8 8 15 2 26
Totale 548